Literature DB >> 8782640

Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan.

H L Chen1, M H Chang, Y H Ni, H Y Hsu, P I Lee, C Y Lee, D S Chen.   

Abstract

OBJECTIVE: To study the seroepidemiology of hepatitis B virus (HBV) infection in children 10 years after a mass hepatitis B vaccination program was begun in Taiwan.
DESIGN: Cross-sectional seroprevalence survey.
SETTING: Cheng-Chung/Chung-Cheng District, Taipei, Taiwan, 1994. SUBJECTS AND METHODS: Serum samples from 1515 healthy children younger than 12 years were tested for HBV markers. The results were compared with a baseline seroepidemiologic study conducted just before the vaccination program was launched in 1984 and with a subsequent study in 1989 in the same area. MAIN
RESULTS: Eighty-seven percent of the children had received at least 3 doses of HBV vaccine. The overall prevalence rate of hepatitis B surface antigenemia decreased from 9.8% in 1984 to 1.3% in 1994. A statistically significant decrease was observed in every age group from 1 to 10 years. The overall prevalence rate of hepatitis B core antibody was 26% in 1984, 15% in 1989, and 4.0% in 1994. This suggests that the risk of horizontal HBV infection has decreased over time, not only because of the protective effect of the vaccine but also because the infection source has diminished. A high prevalence rate of hepatitis B surface antibody (79%) was noted in 1994 as anticipated.
CONCLUSIONS: The Taiwanese mass vaccination program has protected most children younger than 10 years from becoming carriers, reducing both perinatal and horizontal HBV transmission. Mass HBV vaccination has proved to be a successful method to control HBV infection in this hyperendemic area.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8782640

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  46 in total

1.  Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.

Authors:  Hui-Fang Hung; Hsiu-Hsi Chen
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

Review 2.  Preventing and treating hepatitis B infection.

Authors:  Rakesh Aggarwal; Piyush Ranjan
Journal:  BMJ       Date:  2004-11-06

3.  Future perspectives for hepatocellular carcinoma.

Authors:  W Y Lau
Journal:  HPB (Oxford)       Date:  2003       Impact factor: 3.647

4.  Effects of vaccine-acquired polyclonal anti-HBs antibodies on the prevention of HBV infection of non-vaccine genotypes.

Authors:  Masaki Kato; Susumu Hamada-Tsutsumi; Chiaki Okuse; Aiko Sakai; Nobuyuki Matsumoto; Masaaki Sato; Toshiyuki Sato; Mitsumi Arito; Kazuki Omoteyama; Naoya Suematsu; Kazuki Okamoto; Takanobu Kato; Fumio Itoh; Ryo Sumazaki; Yasuhito Tanaka; Hiroshi Yotsuyanagi; Tomohiro Kato; Manae Suzuki Kurokawa
Journal:  J Gastroenterol       Date:  2017-02-14       Impact factor: 7.527

Review 5.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

6.  HLA-DPB1 and anti-HBs titer kinetics in hepatitis B booster recipients who completed primary hepatitis B vaccination during infancy.

Authors:  T-W Wu; C-C Chu; H-W Chang Liao; S-K Lin; T-Y Ho; M Lin; H H Lin; L-Y Wang
Journal:  Genes Immun       Date:  2013-11-28       Impact factor: 2.676

7.  Epidemiology of hepatitis B virus infection in Albania.

Authors:  Bashkim Resuli; Skerdi Prifti; Bledar Kraja; Tatjana Nurka; Mimoza Basho; Edita Sadiku
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

8.  Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children.

Authors:  Hilton Whittle; Shabbar Jaffar; Michael Wansbrough; Maimuna Mendy; Uga Dumpis; Andrew Collinson; Andrew Hall
Journal:  BMJ       Date:  2002-09-14

Review 9.  Molecular cancer prevention: Current status and future directions.

Authors:  Karen Colbert Maresso; Kenneth Y Tsai; Powel H Brown; Eva Szabo; Scott Lippman; Ernest T Hawk
Journal:  CA Cancer J Clin       Date:  2015-08-18       Impact factor: 508.702

10.  Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment.

Authors:  Yan Liu; Felicia Wu
Journal:  Environ Health Perspect       Date:  2010-02-19       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.